THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved updated safety information, including a boxed warning in the prescribing information for the class of drugs known as Erythropoiesis-stimulating Agents (ESAs), including Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa).
